[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649071":3},{"organization":4,"armGroups":7,"interventions":50,"overallOfficials":55,"centralContacts":81,"locations":91,"responsibleParty":108,"collaborators":55,"id":112,"slug":113,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":55,"eligibilityCriteria":117,"healthyVolunteers":114,"sex":118,"minAge":119,"maxAge":55,"enrollmentInfo":120,"targetDuration":55,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":55,"overallStatus":130,"whyStopped":55,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Zhejiang University","OTHER",[8,15,20,25,30,35,40,45],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A","EXPERIMENTAL","patients with FGFR mutation. FGFR mutation inhibitor with GP\u002FGEMOX.",[13,14],"Drug: FGFR Inhibitor","Device: Chemotherapy: GP\u002FGEMOX",{"label":16,"type":10,"description":17,"interventionNames":18},"Arm B","patients with IDH1 mutation. IDH1 mutation inhibitor with GP\u002FGEMOX",[19,14],"Drug: IDH1 mutation inhibitor",{"label":21,"type":10,"description":22,"interventionNames":23},"Arm C","Patients with KRAS mutation. KRAS mutation inhibitor with GP\u002FGEMOX",[24,14],"Drug: KRAS mutation inhibitor",{"label":26,"type":10,"description":27,"interventionNames":28},"Arm D","Patients with NTRK mutation. NTRK mutation inhibitor with GP\u002FGEMOX.",[29,14],"Drug: NTRK mutation inhibitor",{"label":31,"type":10,"description":32,"interventionNames":33},"Arm E","Patients with BRAF V600E mutation. BRAF V600E mutation inhibitor with GP\u002FGEMOX.",[34,14],"Drug: BRAF V600E mutation inhibitor",{"label":36,"type":10,"description":37,"interventionNames":38},"Arm F","Patients with BRCA 1\u002F2 mutation. BRCA 1\u002F2 mutation inhibitor with GP\u002FGEMOX.",[39,14],"Drug: BRCA 1\u002F2 mutation inhibitor",{"label":41,"type":10,"description":42,"interventionNames":43},"Arm G","Patients with HER2 positive. Trastuzumab rezetecan with GP\u002FGEMOX.",[44,14],"Drug: HER2 target therapy",{"label":46,"type":10,"description":47,"interventionNames":48},"Arm H","Patients without any known target. ICI with GP\u002FGEMOX.",[49,14],"Drug: Immune Checkpoint Inhibitors",[51,56,59,62,65,68,71,74,77],{"type":52,"name":53,"description":53,"armGroupLabels":54,"otherNames":55},"DRUG","FGFR Inhibitor",[9],null,{"type":52,"name":57,"description":57,"armGroupLabels":58,"otherNames":55},"IDH1 mutation inhibitor",[16],{"type":52,"name":60,"description":60,"armGroupLabels":61,"otherNames":55},"KRAS mutation inhibitor",[21],{"type":52,"name":63,"description":63,"armGroupLabels":64,"otherNames":55},"NTRK mutation inhibitor",[26],{"type":52,"name":66,"description":66,"armGroupLabels":67,"otherNames":55},"BRAF V600E mutation inhibitor",[31],{"type":52,"name":69,"description":69,"armGroupLabels":70,"otherNames":55},"BRCA 1\u002F2 mutation inhibitor",[36],{"type":52,"name":72,"description":72,"armGroupLabels":73,"otherNames":55},"HER2 target therapy",[41],{"type":52,"name":75,"description":75,"armGroupLabels":76,"otherNames":55},"Immune Checkpoint Inhibitors",[46],{"type":78,"name":79,"description":79,"armGroupLabels":80,"otherNames":55},"DEVICE","Chemotherapy: GP\u002FGEMOX",[9,16,21,26,31,36,41,46],[82,87],{"name":83,"role":84,"phone":85,"phoneExt":55,"email":86},"Tingbo Liang, MD","CONTACT","86+19941463683","liangtingbo@zju.edu.cn",{"name":88,"role":84,"phone":89,"phoneExt":55,"email":90},"Yiwen Chen, MD","86+15088682641","yiwenchen0705@126.com",[92],{"facility":93,"status":55,"city":94,"state":95,"zip":96,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":104,"contacts":105},"The First Affiliated Hospital of Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000","China","CN",{"type":100,"coordinates":101},"Point",[102,103],120.16142,30.29365,{"lat":103,"lon":102},[106],{"name":107,"role":84,"phone":85,"phoneExt":55,"email":90},"Yiwen Chen",{"type":109,"investigatorFullName":110,"investigatorTitle":111,"investigatorAffiliation":5,"oldNameTitle":55,"oldOrganization":55},"PRINCIPAL_INVESTIGATOR","TingBo Liang","The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine","100649071","phase-2-precision-integrated-strategies-and-efficacy-evaluation-for-biliary-tract-cancers-an-umbrella-platform-study-100649071",false,"NCT07729917","Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study","Inclusion Criteria:\n\n* The patient voluntarily joins this study and signs the informed consent form.\n* Age: ≥18 years, male or female.\n* Histologically or cytologically confirmed advanced biliary tract malignancies, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer.\n* No prior systemic therapy for advanced BTC (biliary tract cancer).\n* At least one measurable lesion as per RECIST v1.1 (spiral CT scan long diameter ≥10 mm or short diameter of enlarged lymph node ≥15 mm; lesions previously treated with local therapy may be considered target lesions only after documented progression according to RECIST v1.1).\n* ECOG performance status: 0-1.\n* Expected survival ≥12 weeks.\n* Adequate major organ function.\n* Female subjects of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days before the first dose, must not be breastfeeding, and must voluntarily agree to use effective contraceptive measures during the study period and for 6 months after the last dose of chemotherapy. For male subjects with a female partner of childbearing potential, they must be surgically sterile or agree to use effective contraceptive measures during the study period and for 3 months after the last dose of chemotherapy; sperm donation is not allowed during the study.\n* Subjects are expected to have good compliance and be able to follow the protocol requirements for efficacy and adverse event follow-up.\n\nExclusion Criteria:\n\n* Has another active malignancy other than BTC within 5 years or concurrently.\n* Has poorly controlled cardiac clinical symptoms or diseases.\n* Has hypertension that cannot be reduced to normal range with antihypertensive medication; has a history of hypertensive crisis or hypertensive encephalopathy.\n* Any clinically significant gastrointestinal disorders, including bleeding, inflammation, obstruction, or diarrhea \\> grade 2.\n* Has experienced thrombotic or embolic events within 6 months before the start of study treatment.\n* Use of strong CYP3A4\u002FCYP2C19 inducers (including rifampin and its analogues, and St. John's Wort) or strong CYP3A4\u002FCYP2C19 inhibitors and\u002For strong UGT1A inhibitors within 14 days prior to signing the informed consent form.\n* Has uncontrolled infection at screening.\n* Patients with congenital or acquired immunodeficiency.\n* Has a history of brain metastases or has brain metastases.\n* Women who are pregnant or plan to become pregnant during the study treatment period.\n* Other patients deemed unsuitable for inclusion by the treating physician.","ALL","18 Years",{"count":121,"type":122},240,"ESTIMATED","INTERVENTIONAL",[125],"PHASE2","This study is a prospective, multicenter, open-label, umbrella phase II clinical trial. Based on different multigene expression profiling subtypes and potential molecular characteristics of various pathways, 8 treatment arms and 13 treatment groups are preliminarily designed. After successful screening, investigators will assign eligible subjects to a treatment group based on the patient's genetic test report (if available) and performance status. For subjects without a genetic test report, they will be allocated to Arm H to receive immunotherapy combined with chemotherapy or other regimens.",[128,129],"Bile Duct Carcinoma","Cholangiocarcinoma","NOT_YET_RECRUITING","2026-07-27",{"date":133,"type":134},"2026-07-28","ACTUAL",{"date":136,"type":122},"2026-08-10",{"date":138,"type":122},"2030-12-31",{"name":5,"class":6},1]